Hepatic Oncology最新文献

Management of hepatocellular carcinoma prior to liver transplantation: latest developments. 肝移植前肝细胞癌的处理：最新进展。

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-08-23 DOI: 10.1080/20450923.2025.2549676

Antoine Robert, Thomas M Hunold, Neehar D Parikh

{"title":"Management of hepatocellular carcinoma prior to liver transplantation: latest developments.","authors":"Antoine Robert, Thomas M Hunold, Neehar D Parikh","doi":"10.1080/20450923.2025.2549676","DOIUrl":"10.1080/20450923.2025.2549676","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts transplant to patients with early HCC, and priority for transplant is granted after 6 months on the waitlist, thus patients often require therapies for cancer control while awaiting liver transplantation. The most commonly applied therapies for HCC in patients awaiting liver transplantation are locoregional therapies, including ablative, radiation, and arterial based therapies. Using these therapies patient can be effectively bridged or downstaged to liver transplantation, however there are risks of progressive liver decompensation with locoregional therapies in patients with portal hypertension. There are emerging data for the use of immune checkpoint inhibitor-based immunotherapies in the treatment of HCC. While there has been concern for rejection with the administration of immunotherapy prior to liver transplantation, early data suggest that the risk can be minimized with sufficient washout time prior to liver transplantation. Herein we aim to review management strategies for patients with HCC awaiting liver transplantation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2549676"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update. 肝动脉输注化疗在不可切除的肝细胞癌患者中的应用：3年生存更新。

IF 1.2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-06-17 DOI: 10.1080/20450923.2025.2516994

Shiguang Chen, Wenchang Yu, Xiaolong Wang, Weifu Liu

引用次数: 0

Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy. 推进肝细胞癌的精准医学：液体活检、免疫微环境、单核苷酸多态性和转化治疗的当前挑战和未来方向

IF 1.2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-04-22 DOI: 10.1080/20450923.2025.2493457

Miho Akabane, Yuki Imaoka, Jun Kawashima, Timothy M Pawlik

{"title":"Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy.","authors":"Miho Akabane, Yuki Imaoka, Jun Kawashima, Timothy M Pawlik","doi":"10.1080/20450923.2025.2493457","DOIUrl":"https://doi.org/10.1080/20450923.2025.2493457","url":null,"abstract":"Hepatocellular carcinoma (HCC) remains a health concern characterized by heterogeneity and high mortality. Surgical resection, radiofrequency ablation, trans-arterial chemoembolization, and liver transplantation offer potentially curative treatments for early-stage disease, but recurrence remains high. Most patients present with advanced-stage HCC, where locoregional therapies are less effective, and systemic treatments-primarily multi-kinase inhibitors and immune checkpoint inhibitors-often yield limited responses. Precision medicine aims to tailor therapy to molecular and genetic profiles, yet its adoption in HCC is hindered by inter-/intra-tumoral heterogeneity and limited biopsy availability. Advances in molecular diagnostics support reintroducing tissue sampling to better characterize genetic, epigenetic, and immunological features. Liquid biopsy offers a minimally invasive method for capturing real-time tumor evolution, overcoming spatial and temporal heterogeneity. Artificial intelligence and machine learning are revolutionizing biomarker discovery, risk stratification, and treatment planning by integrating multi-omics data. Immunological factors such as tumor-infiltrating lymphocytes, natural killer cells, macrophages, and fibroblasts have emerged as determinants of HCC progression and treatment response. Conversion therapy-combining systemic agents with locoregional treatments-has showndemonstrated promise in downstaging unresectable HCC. Ongoing efforts to refine biomarker-driven approaches and optimize multi-modality regimens underscore precision medicine's potential to improve outcomes. PubMed (January 2002-February 2025) was searched for relevant studies.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2493457"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies. HES V2.0在HCC检测方面超过GALAD：多维生物标志物评分和研究综述

IF 1.2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-04-30 DOI: 10.1080/20450923.2025.2494446

Fouad Jaber, Hashem B El-Serag

{"title":"HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies.","authors":"Fouad Jaber, Hashem B El-Serag","doi":"10.1080/20450923.2025.2494446","DOIUrl":"https://doi.org/10.1080/20450923.2025.2494446","url":null,"abstract":"This was a narrative review of select studies published through September of 2024. We review the shift toward multi-dimensional scores such as HCC early detection screening (HES), GALAD, ASAP, and mt-HBT represents a significant advancement in biomarker research for hepatocellular carcinoma (HCC) detection. Unlike single biomarker approaches, these scores integrate various clinical and biochemical factors to enhance predictive accuracy by reflecting different complementary aspects of disease progression and HCC oncogenesis. Proper testing and validation of biomarker scores in phase 3 biomarker studies is essential before wide use can be recommended. We also review the comparative performance of biomarker scores in phase 3 studies. The new version of HES (HES V2.0) which includes AFP, AFP L3, DCP, and changes in their levels the past one year, if available, in addition to age, platelets, albumin, ALT and underlying liver disease etiology outperforms GALAD in detecting early-stage HCC with overall 6.7% higher sensitivity, and ASAP with 13.4%-18.0% higher sensitivity, both at fixed 90% specificity. HES V2.0 is a leading candidate biomarker score for prospective testing in clinical studies of early HCC detection.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2494446"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation. 美国早期HCC患者切除或消融治疗的现实世界治疗模式和结果

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-07-24 DOI: 10.1080/20450923.2025.2530377

Neehar D Parikh, Ravi Patel, Jenny Hu, Heide A Stirnadel-Farrant, Nehemiah Kebede, Cindy Wang, Kirema Garcia-Reyes

{"title":"Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation.","authors":"Neehar D Parikh, Ravi Patel, Jenny Hu, Heide A Stirnadel-Farrant, Nehemiah Kebede, Cindy Wang, Kirema Garcia-Reyes","doi":"10.1080/20450923.2025.2530377","DOIUrl":"10.1080/20450923.2025.2530377","url":null,"abstract":"Aim: Real-world outcomes in early-stage hepatocellular carcinoma (eHCC) are not well characterized. We aimed to evaluate treatment patterns and long-term outcomes in patients with eHCC treated with resection or ablation in the United States.Materials and methods: We conducted a retrospective study with Optum's de-identified Market Clarity Data. Patient characteristics, treatment patterns, and overall survival (OS) were assessed in adults with eHCC treated with resection or ablation between July 2016 and March 2021.Results: Of 649 patients who met inclusion criteria, 59.3%, 37.3%, and 3.4% underwent ablation only, resection only, or both, as their initial treatment, respectively. Median age was 64.0 years; most patients were male (72.9%) and White (65.5%). Subsequent treatment was received in 47.1% of patients. The median (quartile 1-3) time to first subsequent treatment was 216 (89.3-414.3) days. The most common subsequent treatments included embolization (22.7%) and ablation (15.6%). In total, 35.7% of patients died post-index. Median OS was 67.7 (95% CI: 56.4-not estimable) months. Estimated 24-month OS was 79.0% (95% CI: 75.0-82.0).Conclusions: Our results highlight the need for post-treatment surveillance and the potential role for neoadjuvant and/or adjuvant treatments to improve outcomes in patients with eHCC treated with resection or ablation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2530377"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape. 循环肿瘤DNA在胆道癌中的整合：新兴景观。

IF 1.2

Hepatic Oncology Pub Date : 2024-12-31 Epub Date: 2024-10-09 DOI: 10.1080/20450923.2024.2403334

Joy A Awosika, Cecilia Monge, Tim F Greten

{"title":"Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape.","authors":"Joy A Awosika, Cecilia Monge, Tim F Greten","doi":"10.1080/20450923.2024.2403334","DOIUrl":"10.1080/20450923.2024.2403334","url":null,"abstract":"Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. Molecular profiling of biliary tract cancers (BTCs) has changed the treatment landscape positively by prolonging survival in an aggressively fatal malignancy in its advanced stages. The acquisition of tissue tumor DNA for genomic analysis in BTC is often anatomically challenging, limited by quantity and quality. In response, ctDNA has emerged as a noninvasive means of molecular profiling. The utility of both plasma and bile ctDNA has been explored in several studies demonstrating the high mutation detection rates and the ability to isolate targetable mutations when present. In addition, the concordance between plasma and tissue DNA provides validity in utilizing ctDNA results to infer treatment decisions. Analysis of ctDNA in BTC has also provided prognostic information and facilitated evaluation of clonal evolution with ease of serial measurements. Insight into novel mechanisms of resistance to targeted therapies are being uncovered in ctDNA. As research endeavors continue to deepen our understanding in the field particularly in the space of ctDNA surveillance after curative intent, the tremendous progress made so far has enabled integration of ctDNA into the clinical practice of BTCs.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"11 1","pages":"2403334"},"PeriodicalIF":1.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases. 免疫疗法在消化道癌症肝转移患者总生存期中的作用。

IF 1.2

Hepatic Oncology Pub Date : 2024-12-31 Epub Date: 2024-09-27 DOI: 10.1080/20450923.2024.2403323

Taoyuan M Beninato, Saber A Amin, Michael J Baine, Chi Lin

引用次数: 0

APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage. 肝细胞癌的APT成像在肿瘤缩小之前预示着有效的治疗反应。

IF 1.2

Hepatic Oncology Pub Date : 2024-12-31 Epub Date: 2024-09-12 DOI: 10.1080/20450923.2024.2389031

Xiaojing Wang, Keisuke Ishimatsu, Junjie Li, Xiaodong Wen, Weijun Ou, Arnida Anwar, Jaideep Chaudhary, Masaya Takahashi, A Dean Sherry, Ian R Corbin

{"title":"APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage.","authors":"Xiaojing Wang, Keisuke Ishimatsu, Junjie Li, Xiaodong Wen, Weijun Ou, Arnida Anwar, Jaideep Chaudhary, Masaya Takahashi, A Dean Sherry, Ian R Corbin","doi":"10.1080/20450923.2024.2389031","DOIUrl":"10.1080/20450923.2024.2389031","url":null,"abstract":"Aim: The aim of this study was to assess the utility of weighted amide proton transfer (APTw) MRI in three different rodent models of hepatocellular carcinoma (HCC).Methods: APTw MRI was evaluated in models of diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft and human HepG2 ectopic xenograft.Results: All models of HCC showed a higher APTw signal over the surrounding normal tissues. In the DEN model, the APTw signal could differentiate HCC lesions from benign nodules. Intra-arterial administration of low-density lipoprotein docosahexaenoic acid (LDL-DHA) nanoparticles to N1S1 xenografts rapidly lowered the tumor APTw signal within 72 h. Direct injections of LDL-DHA nanoparticles into HepG2 xenografts also showed similar therapeutic responses.Conclusion: We have demonstrated the utility of APTw imaging in the diagnostic/therapeutic management of HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"11 1","pages":"2389031"},"PeriodicalIF":1.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11407511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of long-term clinical outcomes between radiofrequency ablation and hepatic resection in patients with small (≤2 cm) hepatocellular carcinoma. 射频消融与肝切除术治疗小（≤2 cm）肝癌的长期临床效果比较

IF 1.2

Hepatic Oncology Pub Date : 2024-12-31 Epub Date: 2024-10-07 DOI: 10.1080/20450923.2024.2403331

Young Mi Hong

{"title":"Comparison of long-term clinical outcomes between radiofrequency ablation and hepatic resection in patients with small (≤2 cm) hepatocellular carcinoma.","authors":"Young Mi Hong","doi":"10.1080/20450923.2024.2403331","DOIUrl":"10.1080/20450923.2024.2403331","url":null,"abstract":"Aim: The present study aimed to compare the long-term survival outcomes of hepatic resection (HR) and radiofrequency ablation (RFA) in patients with single small (≤2 cm) hepatocellular carcinoma (HCC).Materials & methods: This retrospective study enrolled patients with a single small HCC measuring 2 cm or smaller underwent HR or RFA as their initial treatment.Results: Overall survival (OS) was significantly higher in the HR group than in the RFA group, while no significant difference was observed in recurrence free survival (RFS) between the two groups. However, after propensity score matching, both OS and RFS in the HR group were significantly higher than in the RFA group. Multivariate analysis showed that patients with hepatitis B virus infection, elevated prothrombin-induced by vitamin K absence or antagonist-II, and albumin-bilirubin (ALBI) grade 2/3 before treatment had poorer OS. Patients with ALBI grade 1 in the HR group demonstrated the highest OS.Conclusion: HR showed significantly better long-term OS and RFS compared with RFA in patients with as a single HCC (≤2 cm). Moreover, the ALBI grade may help identify patients who would benefit from HR or RFA.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"11 1","pages":"2403331"},"PeriodicalIF":1.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada. 利用加拿大不列颠哥伦比亚省的真实数据了解肝细胞癌患者的治疗历程。

IF 5

Hepatic Oncology Pub Date : 2024-03-14 eCollection Date: 2023-12-01 DOI: 10.2217/hep-2023-0004

Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies

引用次数: 0